Cogent Biosciences (COGT) Treasury Shares (2017 - 2025)
Cogent Biosciences (COGT) posted quarterly Treasury Shares of $539000.0 for Q4 2025, up 573.75% year-over-year from $80000.0 in Q4 2024, and up 573.75% quarter-over-quarter from $80000.0 in Q4 2024.
Cogent Biosciences (COGT) Treasury Shares (2017 - 2025) Analysis & Trends
Cogent Biosciences (COGT) has reported Treasury Shares for 9 consecutive years, with $539000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Treasury Shares rose 573.75% year-over-year to $539000.0; the TTM figure through Dec 2025 stood at $539000.0 (up 573.75% YoY), while the FY2025 annual figure was $4.0 million, up 47.02% from the prior year.
- Treasury Shares rose to $539000.0 in Q4 2025 per COGT's latest filing, from $80000.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $2.5 million in Q4 2023 and bottomed at $80000.0 in Q4 2024.
- Historically, Treasury Shares has averaged $454754.5 across 5 years, with a median of $103289.0 in 2021.
- Annual changes were most pronounced in 2024 — Treasury Shares tumbled 96.8% — and 2025, when it surged 573.75%.
- Cogent Biosciences' Treasury Shares stood at $103289.0 in 2021, then retreated by 7.7% to $95334.0 in 2022, then soared by 2522.36% to $2.5 million in 2023, then sank by 96.8% to $80000.0 in 2024, then soared by 573.75% to $539000.0 in 2025.
- Business Quant data shows COGT's Treasury Shares at $539000.0 in Q4 2025, $80000.0 in Q4 2024, and $2.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 539,000.00 |
| Dec 31, 2025 | 539,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Mar 31, 2022 | 95,334.00 |
| Mar 31, 2022 | 95,334.00 |
| Dec 31, 2021 | 103,289.00 |
| Dec 31, 2021 | 103,289.00 |
| Sep 30, 2021 | 103,289.00 |
| Sep 30, 2021 | 103,289.00 |
| Jun 30, 2021 | 103,289.00 |
| Jun 30, 2021 | 103,289.00 |
| Mar 31, 2021 | 113,835.00 |
| Mar 31, 2021 | 113,835.00 |
| Dec 31, 2020 | 132,244.00 |
| Dec 31, 2020 | 132,244.00 |
| Sep 30, 2020 | 163,325.00 |
| Sep 30, 2020 | 163,325.00 |